Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca supports mental health research of two UK charities

This article was originally published in Scrip

Executive Summary

AstraZenecais sponsoring a project set up by the two UK mental health charities – Rethink and MDF The BiPolar Organisation – to help increase the understanding of factors affecting recovery from mental health disorders and ultimately improve treatment. The company will provide £30,000 to the charities. The project will conduct interviews with patients and will involve interviewers who have themselves previously experienced mental health difficulties. They will work with research subjects in finding out what "recovery"' means for patients in a bid to create better understanding between doctors and patients. A report will be provided to psychiatrists and new service users later in the year. Commenting on the project, AstraZeneca said that the insights into the recovery process provided by the research would enable clinical practice to be adapted accordingly. Rethink estimates that 1% of people live with bipolar disorder in the UK, and around 1% of the population will experience schizophrenia at some time in their lives. Recovery from these conditions can be slow.

You may also be interested in...

Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts